Novo Nordisk has collaborated with relevant authorities to determine a new approach for further development of concizumab. Credit: Novo Nordisk.

Novo Nordisk is set to resume the Phase III explorer 6, 7 and 8 clinical trials of concizumab as a prophylaxis treatment in patients with haemophilia A and B, with or without inhibitors.

The studies were temporarily stopped in March this year after non-fatal thrombotic events were reported in three participants.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Novo Nordisk has collaborated with relevant authorities to determine a new approach for further development of the drug.

All available data was analysed and new safety measures and guidelines have been agreed with the US Food and Drug Administration (FDA).

Novo Nordisk executive vice-president and chief scientific officer Mads Krogsgaard Thomsen said: “I am pleased that we are able to safely restart the explorer trials. This emphasises Novo Nordisk’s long-term dedication to the haemophilia community and our commitment to develop new subcutaneous prophylaxis options for all haemophilia patients.”

Concizumab is a monoclonal antibody designed to target the tissue factor pathway inhibitor (TFPI). The drug is intended to prevent bleeding in haemophilia A and B patients after subcutaneous administration.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Novo Nordisk launched the Phase III ‘explorer7’ trial of the drug in October last year in patients with haemophilia A or B with inhibitors towards FVIII or FIX.

The trial is intended to assess the safety and efficacy of a once-daily prophylactic subcutaneous dose of the drug given in a pen device to decrease the number of bleeds.

Meanwhile, the ‘explorer8’ study was started in November last year in haemophilia A or B patients without inhibitors. The trials are set to recruit a total of around 293 patients across 32 countries.

In September last year, Novo Nordisk reported positive data from the Phase II REAL 3 trial of somapacitan in children with growth hormone deficiency (GHD).